The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
KEYNOTE-630: Phase 3 study of adjuvant pembrolizumab versus placebo in patients with high-risk, locally advanced cutaneous squamous cell carcinoma.
 
Jessica Lyn Geiger
Research Funding - Genentech/Roche (Inst); Regeneron (Inst)
 
Gregory A. Daniels
Honoraria - Sanofi/Regeneron
Consulting or Advisory Role - Sanofi/Regeneron
Speakers' Bureau - Array BioPharma; Regeneron; Sanofi/Regeneron
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Nektar (Inst); Viralytics (Inst)
 
Ezra E.W. Cohen
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; EMD Serono; Human Longevity, Inc; Incyte; Mavu Pharmaceutical; Merck; Nanobiotix; Pfizer
 
Joy Yang Ge
Employment - Merck Sharp & Dohme
Stock and Other Ownership Interests - Merck Sharp & Dohme
 
Burak Gumuscu
Employment - Merck
Stock and Other Ownership Interests - Merck
Travel, Accommodations, Expenses - Merck
 
Ramona F. Swaby
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Anne Lynn S. Chang
Consulting or Advisory Role - Merck; Novartis; Regeneron
Research Funding - Merck; Novartis; Regeneron
Other Relationship - Accent Therapeutics (I); Epinomics (I)